A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.
Understand this study
Who could participate?
This study is for people with ADHD. Listed age limits: 4 years to 5 years. Other eligibility criteria apply.
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Not clearly listed
- Age range
- From 4 Years to 5 Years
- Official registry ID
- NCT03580005
- Official title
Show the full official title
A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Quillichew (Methylphenidate Hydrochloride (Hcl)) Extended Release Chewable Tablets (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd)
Recruitment & locations
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pfizer.
Does this study involve medication?
Yes. The study involves medication, including methylphenidate HCl ERCT and Placebo.
Who can participate?
This study is for people with ADHD. Listed age limits: 4 years to 5 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as withdrawn.
